

REMARKS

Claims 1-62 were pending in the application. Claims 2, 5, 9-10, 13-14, 16-17, 24, 26-27, 29-31, 33-34, 36-37, 41-42, 45-46, 49-50, 52-53, 56-57, 60 and 62 have been amended and claims 1, 4, 6, 12, 25, 32, 44, and 48 have been canceled herein. The amendments to the claims are supported throughout the application as filed, and clarify the claimed subject matter or correct typographical errors. Accordingly no new matter is introduced by the amendment.

CONCLUSION

In view of the above amendments, Applicant submits that the claims share a common technical feature and exhibit a single general inventive concept. Accordingly, the restriction requirement imposed for asserted lack of unity of invention has been rendered moot and should be withdrawn. Notwithstanding the foregoing comments, and to render this submission responsive, Applicant provisionally elects claims 1-7, i.e., the claims of Group 1. Applicant further provisionally elects antisense polynucleotide as the species of active agent and acute myelogenous leukemia as the disease. Claim Group 6 has not been provisionally elected and, thus, the requirement to elect a species of polypeptide has been rendered moot. Applicant submits that the pending claims may properly be examined together in the present application and submits that those claims are in condition for allowance.

Dated: February 22, 2008

Respectfully submitted,

By 

William K. Merkel

Registration No.: 40,725

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant